X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs DIVIS LABORATORIES - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON DIVIS LABORATORIES BIOCON /
DIVIS LABORATORIES
 
P/E (TTM) x 19.3 32.9 58.6% View Chart
P/BV x 3.0 7.4 41.0% View Chart
Dividend Yield % 0.4 0.6 62.9%  

Financials

 BIOCON    DIVIS LABORATORIES
EQUITY SHARE DATA
    BIOCON
Mar-18
DIVIS LABORATORIES
Mar-18
BIOCON /
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,1881,142 104.0%   
Low Rs305533 57.2%   
Sales per share (Unadj.) Rs68.7146.6 46.9%  
Earnings per share (Unadj.) Rs7.633.0 22.9%  
Cash flow per share (Unadj.) Rs14.038.4 36.4%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.11.2 11.2%  
Book value per share (Unadj.) Rs86.3222.8 38.7%  
Shares outstanding (eoy) m600.00265.47 226.0%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.95.7 190.1%   
Avg P/E ratio x98.925.3 390.0%  
P/CF ratio (eoy) x53.421.8 245.0%  
Price / Book Value ratio x8.63.8 230.0%  
Dividend payout %13.230.3 43.7%   
Avg Mkt Cap Rs m447,900222,318 201.5%   
No. of employees `0006.110.8 57.1%   
Total wages/salary Rs m9,3114,561 204.2%   
Avg. sales/employee Rs Th6,705.83,616.0 185.5%   
Avg. wages/employee Rs Th1,514.2423.8 357.3%   
Avg. net profit/employee Rs Th736.9814.9 90.4%   
INCOME DATA
Net Sales Rs m41,23438,915 106.0%  
Other income Rs m2,0621,134 181.8%   
Total revenues Rs m43,29640,049 108.1%   
Gross profit Rs m8,29112,617 65.7%  
Depreciation Rs m3,8511,425 270.3%   
Interest Rs m61513 4,624.1%   
Profit before tax Rs m5,88712,313 47.8%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5693,543 44.3%   
Profit after tax Rs m4,5318,770 51.7%  
Gross profit margin %20.132.4 62.0%  
Effective tax rate %26.728.8 92.6%   
Net profit margin %11.022.5 48.8%  
BALANCE SHEET DATA
Current assets Rs m41,48645,351 91.5%   
Current liabilities Rs m21,4136,507 329.1%   
Net working cap to sales %48.799.8 48.8%  
Current ratio x1.97.0 27.8%  
Inventory Days Days64127 50.5%  
Debtors Days Days9495 99.0%  
Net fixed assets Rs m50,66121,160 239.4%   
Share capital Rs m3,000531 565.1%   
"Free" reserves Rs m48,80858,625 83.3%   
Net worth Rs m51,80859,156 87.6%   
Long term debt Rs m17,8980-   
Total assets Rs m99,89767,832 147.3%  
Interest coverage x10.6926.8 1.1%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.40.6 71.9%   
Return on assets %5.212.9 39.8%  
Return on equity %8.714.8 59.0%  
Return on capital %9.620.8 46.2%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m12,05832,359 37.3%   
Fx outflow Rs m7,3489,042 81.3%   
Net fx Rs m4,71023,317 20.2%   
CASH FLOW
From Operations Rs m6,6217,759 85.3%  
From Investments Rs m-6,840-4,783 143.0%  
From Financial Activity Rs m-2,397-3,142 76.3%  
Net Cashflow Rs m-2,612-166 1,573.5%  

Share Holding

Indian Promoters % 40.4 52.0 77.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 11.8 71.2%  
FIIs % 10.7 19.0 56.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.2 115.7%  
Shareholders   109,995 31,796 345.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)

Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jul 17, 2019 (Close)

TRACK BIOCON

BIOCON - AJANTA PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS